Compumedics Limited (CMP) AI Stock Analysis

• Market Cap: AU$54.78M
• Dividend Yield: N/A
• Average Volume (3M): 112.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: 2.49%
• EPS Growth: -268.42%
• Country: AU
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 192,217,900
• 10 Day Avg. Volume: 44,748
• 30 Day Avg. Volume: 112,557
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.50
• Price Target Upside: 78.57% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: AU$0.50 ▲(78.57% Upside)

Compumedics Limited demonstrates positive technical momentum, but significant financial challenges persist, with ongoing net losses and negative cash flow. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield. Improvement in financial performance is needed for a more favorable outlook.

Compumedics Limited Business Overview & Revenue Model

Company Description

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Okti; Grael PSG; Grael DC; Somfit/Somfit Pro, a wearable device; TCM5 FLEX Transcutaneous monitor; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, and persyst software products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.

How the Company Makes Money

Compumedics Limited generates revenue primarily through the sale of its diagnostic equipment and related software solutions. The company offers a range of products including sleep diagnostic systems, neurological monitoring devices, and Doppler blood flow systems. These products are sold to healthcare facilities, research institutions, and distributors worldwide. Additionally, Compumedics may derive income from service contracts, equipment maintenance, and software upgrades, which provide ongoing support and enhancements to their product offerings. Strategic partnerships and collaborations with medical and research organizations also play a role in expanding the company's market reach and driving revenue growth.

Compumedics Limited Financial Statement Overview

Summary

Compumedics Limited is showing revenue growth and stable gross profit margins, positive indicators for future performance. However, the company faces significant challenges with ongoing net losses, negative EBIT, and negative free cash flow. Improving profitability is crucial to enhance financial stability.

Income Statement

Compumedics Limited has shown a positive revenue growth rate of 17.23% from 2023 to 2024, indicating a recovery trend. However, the company continues to experience negative net income and EBIT, resulting in negative net and EBIT margins. Gross profit margins have remained relatively stable, suggesting efficient cost management at the gross level but challenges in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has increased slightly, indicating a moderate level of leverage. The equity ratio stands at 45.11%, which reflects a balanced capital structure but a decrease from previous years. Return on equity remains negative due to net losses, highlighting profitability challenges.

Cash Flow

Compumedics Limited's free cash flow has improved from 2023 to 2024 but remains negative. The operating cash flow to net income ratio is favorable, suggesting that cash flow generation relative to net income is strong. However, the overall negative free cash flow indicates ongoing challenges in generating sufficient cash from operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	50.26M	42.41M	37.76M	35.74M	35.07M
Gross Profit	26.07M	21.59M	19.32M	19.16M	18.01M
EBITDA	2.79M	-5.05M	3.31M	2.56M	-5.42M
Net Income	-338.00K	-6.12M	1.36M	998.00K	-5.84M
Balance Sheet
Total Assets	40.36M	41.18M	41.71M	38.55M	35.53M
Cash, Cash Equivalents and Short-Term Investments	1.89M	3.80M	7.29M	6.77M	6.41M
Total Debt	8.58M	9.47M	6.55M	5.82M	4.80M
Total Liabilities	22.15M	22.89M	18.12M	16.39M	13.73M
Stockholders Equity	18.21M	18.29M	23.59M	22.16M	21.79M
Cash Flow
Free Cash Flow	-986.00K	-4.36M	302.00K	-230.00K	1.15M
Operating Cash Flow	2.00M	49.00K	3.29M	1.32M	5.38M
Investing Cash Flow	-2.99M	-4.41M	-2.98M	-1.55M	-4.23M
Financing Cash Flow	-1.49M	-1.00M	1.61M	-179.00K	448.00K

Compumedics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.30, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.49 is Neutral, neither overbought nor oversold. The STOCH value of 65.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMP.

Compumedics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOM	61 Neutral	163.64M	-46.88	―	―	21.65%	81.40%
CMP	58 Neutral	AU$54.78M	―	-6.35%	―	2.49%	-268.42%
IPD	48 Neutral	73.30M	-3.13	-113.37%	―	23.31%	-17.35%
EMV	46 Neutral	178.30M	-16.91	―	―	―	-257.32%
CBL	44 Neutral	12.02M	-1.46	―	―	14.84%	39.64%
CYC	42 Neutral	93.35M	-6.95	-30.89%	―	34.20%	-23.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Compumedics Limited Corporate Events

Compumedics Expands into Pharmaceutical Clinical Trials with Somfit Sales

Compumedics Limited has announced significant sales of its Somfit devices to major pharmaceutical and clinical research organizations in the USA and Europe, with revenues nearing $2 million. These sales mark a strategic expansion into the pharmaceutical clinical trial market, showcasing Somfit’s advanced capabilities in sleep monitoring and its potential beyond traditional home sleep testing. The contracts underscore the growing importance of sleep data in drug trials and highlight Compumedics’ commitment to diversifying its global business and exploring new growth avenues.

Compumedics Secures $24M Distribution Agreements in China

Compumedics Limited has signed two new 4-year distribution agreements in China, valued at A$24.4 million, with long-term partners. These agreements, which include a minimum 10% annual growth commitment, aim to strengthen Compumedics’ presence in Northern and Eastern China, focusing on sleep diagnostics and neurology. This strategic move is part of Compumedics’ broader effort to diversify and stabilize its revenue streams geographically and across product lines, positioning the company for sustained growth in key international markets, particularly in Asia.

Compumedics Limited Reports Record Sales and Strategic Growth in FY25

Compumedics Limited has announced a record-breaking fiscal year 2025, characterized by a 22% increase in sales orders and a return to profitability. The company’s strategic focus on the US market and SaaS platforms has driven significant growth, with US sales orders up by 115% and SaaS orders increasing by 49%. Looking ahead, Compumedics aims to scale its business model with new product launches and recurring revenue streams, projecting a revenue of at least $70 million and an EBITDA of approximately $9 million for FY26. The launch of the disposable Somfit in the US and the expansion of the MEG systems into the pediatric market are expected to further enhance the company’s market position and revenue potential.

Compumedics Adjusts FY25 Financial Guidance and Confirms FY26 Outlook

Compumedics Limited announced a correction to its financial guidance for FY25, expecting sales orders to exceed $60 million, with reported revenues between $50 million and $55 million, which is below the previously advised $55 million. The company anticipates an EBITDA of about $3 million for FY25, down from the previously advised $5 million. Looking ahead, Compumedics confirms FY26 revenue guidance of at least $70 million, driven by the shipment of MEG orders, with an expected EBITDA of at least $9 million.

Compumedics Secures $1M Somfit Contract with Leading US CRO

Compumedics Limited has secured a significant contract worth $1 million for its Somfit device with a leading pharmaceutical Contract Research Organisation in the USA. This sale is part of Compumedics’ strategy to expand beyond the home sleep testing market into pharmaceutical clinical trials, leveraging Somfit’s ability to directly track brain signals for accurate sleep architecture analysis. The contract highlights the company’s strong growth in the USA, with sales orders reaching $12 million this year, a 130% increase from the previous year. Compumedics anticipates continued growth, projecting sales orders over $60 million for FY25, although revenue and EBITDA expectations have been adjusted due to the rapid business expansion.